An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction

Affiliations

¹ Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada; Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada; Division of Infectious Diseases, Department of Medicine, McGill University, Montréal, Canada. Electronic address: todd.lee@mcgill.ca.
² Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada.
³ Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada; Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada.
⁴ Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

Editorial

Todd C Lee et al. Int J Infect Dis. 2020 Sep.

. 2020 Sep:98:216-217.

doi: 10.1016/j.ijid.2020.06.095. Epub 2020 Jul 2.

¹ Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada; Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada; Division of Infectious Diseases, Department of Medicine, McGill University, Montréal, Canada. Electronic address: todd.lee@mcgill.ca.
² Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada.
³ Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada; Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada.
⁴ Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.

No abstract available

Comment on

1. Arshad S., Kilgore P., Chaudhry Z.S., Jacobsen G., Wang D., Huitsing K. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396–403. doi: 10.1016/j.ijid.2020.06.099. In this issue. - DOI - PMC - PubMed
1. Geleris J., Sun Y., Platt J., Zucker J., Baldwin M., Hripcsak G. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418. - PMC - PubMed
1. Horby P., Lim W.S., Emberson J., Mafham M., Bell J., Linsell L. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. In press. - DOI - PMC - PubMed
1. Kyriacou D.N., Lewis R.J. Confounding by indication in clinical research. J Am Med Assoc. 2016;316(17):1818–1819. - PubMed
1. Paranjpe I., Fuster V., Lala A., Russak A., Glicksberg B.S., Levin M.A. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020 - PMC - PubMed